A system for obtaining clearance comprises a mechanism to identify the user and generate an identification signal; an analytical toilet comprising a bowl to receive excreta from the user; an analyzer configured to analyze the sample to detect one or more antibodies in a sample of the excreta or sputum and to generate an analysis signal; a processor configured to receive the identification signal and the analysis signal; determine therefrom the status of the user with respect to the one or more antibodies; and transmit a report to an authority, the report comprising the identity and the status of the user with respect to the antibodies detected. A method for obtaining clearance comprises linking a user to an analytical toilet; receiving a sample of excreta from the user in the analytical toilet; analyzing the sample of excreta in an analytical toilet to detect one or more antibodies; processing results from the analytical toilet and determining the status of the user with respect to the antibodies detected; submitting the identity and the status of the user with respect to the antibodies detected to an authority.

A lateral flow assay device includes a test strip that is configured to receive a sample fluid and detect a presence of antibodies to one or more of a plurality of proteins of the target pathogen. The lateral flow assay device includes a conjugate pad and a membrane. The conjugate pad contains a plurality of the proteins of the target pathogen, each conjugated with a label. If the sample fluid contains antibodies that are specific to the target pathogen through any of the target pathogen's proteins, a binding takes place between those antibodies and the corresponding tagged protein. The membrane may include a plurality of test lines. Each test line may contain the immobilized binding reagent to one antibody class, resulting in the concentration of all the molecules of that antibody class on the test line.

The invention includes methods and kits for the detection of a virus that may be in a sample. In embodiments, the invention includes a method of detecting a virus in a sample by forming a reaction mixture exposing an aliquot of the sample purportedly containing a virus to an immobilized receptor. A soluble receptor including a detectable label is added to the reaction mixture. A washing step washes the immobilized receptor, and the detectable label is detected.

Disclosed is a covalently-linked multilayered three-dimensional matrix comprising capture molecules, linkers and spacers (referred to as a Molecular Net) for specific and sensitive analyte capture from a sample. Also disclosed herein is a Molecular Net comprising covalently-linked multilayered three-dimensional matrix comprising more than one type of capture molecule and more than one type of linker and may comprise one or more spacer for specific and sensitive capture of more than one type of analyte from a sample. A Molecular Net may comprise a pseudorandom nature. Use of various capture molecules, linkers and spacers in a Molecular Net may confer unique binding properties to a Molecular Net. Porosity, binding affinity, size exclusion abilities, filtration abilities, concentration abilities and signal amplification abilities of a Molecular Net may be varied and depend on the nature of components used in its fabrication. Uses of a Molecular Net may include analyte capture, analyte enrichment, analyte purification, analyte detection, analyte measurement and analyte delivery. Molecular Nets may be used in liquid phase or on solid phases such as nanomaterials, modified metal surfaces, nanospheres, microspheres, microtiter plates, slides, pipettes, cassettes, cartridges, discs, probes, lateral flow devices, microfluidics devices, microfluidics devices, optical fibers and others.

The invention(s) cover a sensor and method of fabrication, the sensor including: a substrate; and a distribution of nanoparticles patterned onto the substrate as a set of regions. In variations, the sensor 100 can further include one or more channels in fluid communication with the distribution of nanoparticles. In variations, different nanoparticle regions can be optionally functionalized with different probe molecules in order to provide additional functionality with respect to the assay(s) being performed using the sensor 100. Additionally or alternatively, in variations, unoccupied regions of the substrate 110 and/or nanoparticle surfaces can optionally include passivated surfaces to prevent non-specific binding, without significantly shifting the LSPR wavelength, in order to significantly improve signal-to-noise ratio (SNR) provided by the sensor. The sensor can be used for performance of multiplexed assays (e.g., for infectious disease panels) with processing of different types of sample material.

Provided herein are systems, devices and methods for the rapid and accurate measurement of analyte particles binding-induced aggregation of reporter particles. In the presence of analyte particles of interest, reporter particles form aggregates which increase in mean particle size as the concentration of analyte increases. From analysis of the mean particle size, determined from sample frames, the presence and/or concentration of analyte can be determined.

The present disclosure provides a rapid test for determining state of an infection (e.g., a coronavirus such as Covid-2019) in a subject. The test may include the steps of detecting of an antibody specific to the pathogen in a blood sample from the subject, and detecting and quantitating the level of at least one inflammatory biomarker in the same subject.

Methods for obtaining a sample from a subject include providing a sample collection room within a retail store; and obtaining a sample from a subject at a retail location. Sample collection rooms may house a sample analysis device or system. Samples may be small, e.g., a finger-stick capillary blood sample.

The invention relates to the diagnosis of a SARS-associated coronavirus, such as a SARS-CoV-2 infection and SARS-CoV-1 infection, using the N_SARS-COV-1 and N_SARS-CoV-2 proteins and antibodies binding to these proteins. The invention reagents, methods and kits for the detection of a SARS-associated coronavirus.

A self-administered tester for infection may include a sample collection element for receiving fluid samples including bodily fluids. The sample collection elements may provide at least a portion of a collected sample to one or more evaluation elements. Each evaluation element may determine whether some evaluation criteria have been satisfied. Result indicators may provide visual indicators showing whether the evaluation criteria were satisfied. The self-administered tester may test for a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection using evaluators associated with the Immunoglobulin G (IgG) antibody and the Immunoglobulin M (IgM) antibody.